Can Fite Biopharma (NYSEAMERICAN:CANF)‘s stock had its “hold” rating reaffirmed by research analysts at Maxim Group in a note issued to investors on Friday, March 9th, Marketbeat reports. They presently have a $7.00 price target on the biotechnology company’s stock. Maxim Group’s price target would indicate a potential upside of 386.11% from the stock’s previous close.
The analysts wrote, “While we anticipated CanFite would need to raise capital we did not anticipate the added dilution announced in today’s raise and the potential impact of raising too little capital which sets up additional dilution.””
Separately, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Can Fite Biopharma in a research note on Thursday, February 1st.
Shares of NYSEAMERICAN:CANF traded up $0.01 during midday trading on Friday, reaching $1.44. The company’s stock had a trading volume of 11,800 shares, compared to its average volume of 189,661. Can Fite Biopharma has a fifty-two week low of $1.24 and a fifty-two week high of $2.75.
A hedge fund recently bought a new stake in Can Fite Biopharma stock. Meitav Dash Investments Ltd. acquired a new stake in shares of Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 155,000 shares of the biotechnology company’s stock, valued at approximately $240,000. Meitav Dash Investments Ltd. owned about 0.93% of Can Fite Biopharma at the end of the most recent quarter. Hedge funds and other institutional investors own 5.12% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Can Fite Biopharma (NYSEAMERICAN:CANF) Rating Reiterated by Maxim Group” was originally posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://theenterpriseleader.com/2018/04/02/can-fite-biopharma-nyseamericancanf-stock-rating-reaffirmed-by-maxim-group.html.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.